FDA May 4, 2026 Celcuity Beats Piqray in Phase 3, Shares Jump 15% Pfizer sold gedatolisib to Celcuity for $10 million upfront in 2021. fda
FDA Apr 20, 2026 Wins Third Phase 3 in COPD: AstraZeneca's Tozorakimab Eyes $5B Peak Tozorakimab now has three phase 3 COPD wins in 2026. fda
Deals Apr 16, 2026 Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year's full-year total of $20.3 billion with three… deals
FDA Apr 13, 2026 Beats Venetoclax: Lilly's Jaypirca Posts 4th Phase 3 Win in CLL Jaypirca chalked up its fourth positive phase 3 readout in chronic lymphocytic leukemia on Monday, and this one rewrites the treatment calculus: it's the… fda
Deals Apr 13, 2026 Regeneron Paid $40M to Enter Radiopharma; Telix Scores Up to $4.3B Regeneron put $40 million on the table Sunday to partner with Telix Pharmaceuticals, the Australian biotech with one of the more active radiopharmaceutical… deals
Deals Apr 5, 2026 Syneron Bio Pulls $150M Series B Four Months After $100M Round Syneron Bio raises $150M Series B, bringing total funding to $250M in four months, backed by AstraZeneca and Abu Dhabi sovereign wealth. deals
Deals Apr 5, 2026 Lilly Pays $115M Upfront in Insilico AI Deal Worth Up to $2.75B Eli Lilly paid $115M upfront for an AI collaboration with Insilico Medicine worth up to $2.75B, with milestone math that heavily favors Lilly. deals
